Neurocrine Q1: INGREZZA sales $303M (+32% YoY), GAAP EPS $0.14, reaffirms FY guidance

NEUROCRINE BIOSCIENCES INC

2022-Q1 EPS reported $0.14 revenue$310,600,000

Net product sales $303M (+32% YoY); total revenue $310.6M incl $5.6M collaboration revenue.
GAAP net income $13.9M ($0.14 diluted EPS) vs $32.1M ($0.33) in Q1 2021.
Non-GAAP net income $29.7M ($0.30 diluted EPS) vs $48.8M ($0.50) prior year.
Cash and marketable securities $1.2B; reiterates 2022 INGREZZA sales guidance $1.25-$1.35B.
Positive Phase 3 valbenazine data in Huntington chorea; sNDA filing expected H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.